Nykode Therapeutics ASA

Research Nykode Therapeutics ASA (NYKD) on Bullrun: market cap NOK 1.40B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerNYKD
ExchangeOL
CountryNorway
SectorHealthcare
IndustryBiotechnology
CurrencyNOK
Market capNOK 1.40B
Financial periodQ1 2026
RevenueUSD 0
Net income-USD 4.11M
Free cash flow-USD 9.61M

Valuation Snapshot

latest market cap is NOK 1.40B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	USD 0	-USD 12.24M	-USD 29.49M	n/a	-0.03	USD 59.86M	USD 2.55M	USD 91.54M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-28	NOK 1.40B	n/a	29.8%	1

Dividend history

Latest trailing dividend snapshot: annual dividend/share 1 NOK.

About Nykode Therapeutics ASA

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial. It also offers VB10.NEO, which is in Phase1b VB-N-02 trial;

Related stock research

Norway stocks Norway Healthcare stocks A-Z stock index

Other Healthcare stocks

Selvaag Bolig ASA (0Q92) Aqua Bio Technology ASA (ABTEC) Arcticzymes Technologies ASA (B4V) Circio Holding ASA (CRNA) Exact Therapeutics AS (EXTX) Lytix Biopharma AS (LYTIX) Oncoinvent ASA (ONCIN) SoftOx Solutions AS (SOFTX) Thor Medical ASA (TRMED) Zelluna ASA (ZLNA) Medistim ASA (0OCD) NORDHEALTH AS NK 1 (6E5)

Frequently asked questions

What is Nykode Therapeutics ASA's market cap?

Nykode Therapeutics ASA's market capitalization is NOK 1.40B.